Page 1807 - Williams Hematology ( PDFDrive )

1782 Part XI: Malignant Lymphoid Diseases Chapter 108: Immunoglobulin Light-Chain Amyloidosis 1783

minimum increase of 300 ng/dL. Finally, liver response is defined as a 29. von Hutten H, Mihatsch M, Lobeck H, et al: Prevalence and origin of amyloid in kidney
50 percent reduction in the abnormal alkaline phosphatase value, with biopsies. Am J Surg Pathol 33(8):1198–1205, 2009.
progression defined as a 50 percent increase of alkaline phosphatase 30. Said SM, Sethi S, Valeri AM, et al: Renal amyloidosis: Origin and clinicopathologic
correlations of 474 recent cases. Clin J Am Soc Nephrol 8(9):1515–1523, 2013.
above the lowest recorded value. Currently, consensus criteria to define 31. Gertz MA, Leung N, Lacy MQ, et al: Clinical outcome of immunoglobulin light chain
response in soft tissues, the gastrointestinal tract, the tongue, the lung, amyloidosis affecting the kidney. Nephrol Dial Transplant 24(10):3132–3137, 2009.
or the peripheral nerve do not exist for AL amyloidosis. 32. Duda SH, Raible RT, Risler T, et al: [Therapeutic bilateral renal artery embolization in
the nephrotic syndrome] [in German]. Dtsch Med Wochenschr 119(3):58–62, 1994.
33. Sher T, Gertz MA: Recent advances in the diagnosis and management of cardiac amy-
REFERENCES 34. Guan J, Mishra S, Falk RH, Liao R: Current perspectives on cardiac amyloidosis. Am J
loidosis. Future Cardiol 10(1):131–146, 2014.
1. Bobon J: [Professor Paul Divry 1889–1967] [in French]. Acta Neurol Psychiatr Belg Physiol Heart Circ Physiol 302(3):H544–H552, 2012.
67(2):143–148, 1967. 35. Suresh R, Grogan M, Maleszewski JJ, et al: Advanced cardiac amyloidosis associated
2. Steensma DP: “Congo” red: Out of Africa? Arch Pathol Lab Med 125(2):250–252, 2001. with normal interventricular septal thickness: An uncommon presentation of infiltra-
3. Cohen AS, Calkins E: Electron microscopic observations on a fibrous component in tive cardiomyopathy. J Am Soc Echocardiogr 27(4):440–447, 2014.
amyloid of diverse origins. Nature 183(4669):1202–1203, 1959. 36. Falk RH: Senile systemic amyloidosis: Are regional differences real or do they reflect
4. Murakami T, Uchino M, Ando M: Genetic abnormalities and pathogenesis of familial different diagnostic suspicion and use of techniques? Amyloid 19 Suppl 1:68–70, 2012.
amyloidotic polyneuropathy. Pathol Int 45(1):1–9, 1995. 37. Leone O, Longhi S, Quarta CC, et al: New pathological insights into cardiac amyloido-
5. Esplin BL, Gertz MA: Current trends in diagnosis and management of cardiac amyloi- sis: Implications for non-invasive diagnosis. Amyloid 19(2):99–105, 2012.
dosis. Curr Probl Cardiol 38(2):53–96, 2013. 38. Singh V, Fishman JE, Alfonso CE: Primary systemic amyloidosis presenting as constric-
6. Fernandez-Flores A: A review of amyloid staining: Methods and artifacts. Biotech His- tive pericarditis. Cardiology 118(4):251–255, 2011.
tochem 86(5):293–301, 2011. 39. Dubrey S, Pollak A, Skinner M, Falk RH: Atrial thrombi occurring during sinus rhythm
7. Picken MM: Non-light-chain immunoglobulin amyloidosis: Time to expand or refine the in cardiac amyloidosis: Evidence for atrial electromechanical dissociation. Br Heart J
spectrum to include light+heavy chain amyloidosis? Kidney Int 83(3):353–356, 2013. 74(5):541–544, 1995.
8. del Pozo Yauner L, Ortiz E, Sanchez R, et al: Influence of the germline sequence on the 40. Morin J, Schreiber WE, Lee C: Sudden death due to undiagnosed primary amyloidosis.
thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins J Forensic Sci 58(Suppl 1):S250–S252, 2013.
72(2):684–692, 2008. 41. Dubrey SW, Rosser G, Dahdal MT, Gillmore JD: Diagnostic dilemma and sudden death
9. Kourelis TV, Kumar SK, Gertz MA, et al: Coexistent multiple myeloma or increased outcome: A case of amyloid cardiomyopathy. Clin Med 12(6):596–597, 2012.
bone marrow plasma cells define equally high-risk populations in patients with immu- 42. Dhoble A, Khasnis A, Olomu A, Thakur R: Cardiac amyloidosis treated with an
noglobulin light chain amyloidosis. J Clin Oncol 31(34):4319–4324, 2013. implantable cardioverter defibrillator and subcutaneous array lead system: Report of a
10. Madan S, Dispenzieri A, Lacy MQ, et al: Clinical features and treatment response of case and literature review. Clin Cardiol 32(8):E63–E65, 2009.
light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple 43. Lin G, Dispenzieri A, Kyle R, et al: Implantable cardioverter defibrillators in patients
myeloma. Mayo Clin Proc 85(3):232–238, 2010. with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793–798, 2013.
11. Kyle RA, Linos A, Beard CM, et al: Incidence and natural history of primary sys- 44. Mohty D, Damy T, Cosnay P, et al: Cardiac amyloidosis: Updates in diagnosis and man-
temic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79(7): agement. Arch Cardiovasc Dis 106(10):528–540, 2013.
1817–1822, 1992. 45. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD: A prospective evaluation of the
12. Pardanani A, Witzig TE, Schroeder G, et al: Circulating peripheral blood plasma transthyretin Ile122 allele frequency in an African-American population. Amyloid
cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 12(2):127–130, 2005.
101(3):827–830, 2003. 46. Afolabi I, Hamidi Asl K, Nakamura M, et al: Transthyretin isoleucine-122 mutation in
13. Fonseca R, Ahmann GJ, Jalal SM, et al: Chromosomal abnormalities in systemic amy- African and American blacks. Amyloid 7(2):121–125, 2000.
loidosis. Br J Haematol 103(3):704–710, 1998. 47. Dispenzieri A, Gertz MA, Kumar SK, et al: High sensitivity cardiac troponin T in
14. Bryce AH, Ketterling RP, Gertz MA, et al: Translocation t(11;14) and survival of patients with immunoglobulin light chain amyloidosis. Heart 100(5):383–388, 2014.
patients with light chain (AL) amyloidosis. Haematologica 94(3):380–386, 2009. 48. Kumar S, Dispenzieri A, Lacy MQ, et al: Revised prognostic staging system for light
15. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in chain amyloidosis incorporating cardiac biomarkers and serum free light chain mea-
474 cases. Semin Hematol 32(1):45–59, 1995. surements. J Clin Oncol 30(9):989–995, 2012.
16. Lesser BA, Leeper KV Jr, Conway W. Obstructive sleep apnea in amyloidosis treated 49. Girnius S, Seldin DC, Cibeira MT, Sanchorawala V: New hematologic response crite-
with nasal continuous positive airway pressure. Arch Intern Med 148(10):2285–2287, ria predict survival in patients with immunoglobulin light chain amyloidosis treated
1988. with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol
17. Park MA, Mueller PS, Kyle RA, et al: Primary (AL) hepatic amyloidosis: Clinical fea- 31(21):2749–2750, 2013.
tures and natural history in 98 patients. Medicine (Baltimore) 82(5):291–298, 2003. 50. Leung N, Glavey SV, Kumar S, et al: A detailed evaluation of the current renal response
18. Neri A, Rubino P, Macaluso C, Gandolfi SA: Light-chain amyloidosis mimicking giant criteria in AL amyloidosis: Is it time for a revision? Haematologica 98(6):988–992, 2013.
cell arteritis in a bilateral anterior ischemic optic neuropathy case. BMC Ophthalmol 51. Palladini G, Dispenzieri A, Gertz MA, et al: New criteria for response to treatment in immu-
13:82, 2013. noglobulin light chain amyloidosis based on free light chain measurement and cardiac
19. Foli A, Palladini G, Caporali R, et al: The role of minor salivary gland biopsy in the diag- biomarkers: Impact on survival outcomes. J Clin Oncol 30(36):4541–4549, 2012.
nosis of systemic amyloidosis: Results of a prospective study in 62 patients. Amyloid 18 52. White JA, Kim HW, Shah D, et al: CMR imaging with rapid visual T1 assessment pre-
(Suppl 1):80–82, 2011. dicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging
20. Aljaroudi WA, Desai MY, Tang WH, et al: Role of imaging in the diagnosis and manage- 7(2):143–156, 2014.
ment of patients with cardiac amyloidosis: State of the art review and focus on emerging 53. Mesquita D, Nobre C, Thomas B, et al: Cardiac amyloidosis: Diagnosis using delayed
nuclear techniques. J Nucl Cardiol 21(2):271–283, 2014. enhancement cardiac magnetic resonance imaging sequences. Rev Port Cardiol
21. Glaudemans AW, Slart RH, Noordzij W, et al: Utility of 18F-FDG PET(/CT) in patients 32(11):941–945, 2013.
with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging 40(7):1095–1101, 54. Gerbaud E, Lederlin M, Laurent F: Value of phase-sensitive inversion recovery
2013. sequence to perform and analyse late gadolinium enhancement in cardiac amyloidosis.
22. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, et al: Diagnostic performance and Arch Cardiovasc Dis 102(12):859–860, 2009.
prognostic value of extravascular retention of 123I-labeled serum amyloid P compo- 55. Glaudemans AW, van Rheenen RW, van den Berg MP, et al: Bone scintigraphy with
nent in systemic amyloidosis. J Nucl Med 48(6):865–872, 2007. technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac
23. Shidham VB, Hunt B, Jardeh SS, et al: Performing and processing FNA of anterior fat involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid
pad for amyloid. J Vis Exp (44), 2010. 21(1):35–44, 2014.
24. Linke RP: On typing amyloidosis using immunohistochemistry. Detailed illustrations, 56. Antoni G, Lubberink M, Estrada S, et al: In vivo visualization of amyloid deposits in the
review and a note on mass spectrometry. Prog Histochem Cytochem 47(2):61–132, 2012. heart with 11C-PIB and PET. J Nucl Med 54(2):213–220, 2013.
25. Schonland SO, Hegenbart U, Bochtler T, et al: Immunohistochemistry in the classifica- 57. Norero B, Perez-Ayuso RM, Duarte I, et al: Portal hypertension and acute liver failure as
tion of systemic forms of amyloidosis: A systematic investigation of 117 patients. Blood uncommon manifestations of primary amyloidosis. Ann Hepatol 13(1):142–149, 2013.
119(2):488–493, 2012. 58. Mousa AY, Abu-Halimah S, Alhalbouni S, et al: Amyloidosis and spontaneous hepatic
26. Sethi S, Vrana JA, Theis JD, et al: Laser microdissection and mass spectrometry-based bleeding, transcatheter therapy for hepatic parenchymal bleeding with massive intrap-
proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 82(2): eritoneal hemorrhage: A case report and review of the literature. Vascular 22(5):
226–234, 2012. 356–360, 2014.
27. Brambilla F, Lavatelli F, Di Silvestre D, et al: Reliable typing of systemic amyloidoses through 59. Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med 79(6):733–748, 2012.
proteomic analysis of subcutaneous adipose tissue. Blood 119(8):1844–1847, 2012. 60. Adams D, Lozeron P, Lacroix C: Amyloid neuropathies. Curr Opin Neurol 25(5):
28. Vrana JA, Gamez JD, Madden BJ, et al: Classification of amyloidosis by laser microdis- 564–572, 2012.
section and mass spectrometry-based proteomic analysis in clinical biopsy specimens. 61. Rajani B, Rajani V, Prayson RA: Peripheral nerve amyloidosis in sural nerve biopsies: A
Blood 114(24):4957–4959, 2009. clinicopathologic analysis of 13 cases. Arch Pathol Lab Med 124(1):114–118, 2000.

Kaushansky_chapter 108_p1773-1784.indd 1782 9/18/15 9:53 AM